Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,421 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02661035 | Allo HSCT Using RIC for Hematological Diseases | completed | Phase 2 | 156 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT03202628 | Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 8 | Mayo ClinicOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05082675 |
| Stem Cell Translpantation in Multiple Myeloma |
| completed |
| Phase 2 |
| 357 |
| European Society for Blood and Marrow TransplantationNETWORK |
| 11 |
| Sep 11, 2023 |
| clinicaltrials |
| NCT01346787 | Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients(CCD) | completed | Phase 2 | 58 | European Myeloma Network B.V.NETWORK | 2 | Sep 8, 2023 | clinicaltrials |
| NCT03201250 | Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 11 | University of NebraskaOTHER | 1 | Sep 8, 2023 | clinicaltrials |
| NCT03759093 | CURATE.AI Optimized Modulation for Multiple Myeloma | unknown | Phase 2 / Phase 3 | 20 | National University Hospital, SingaporeOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT04258683 | A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE | withdrawn | Phase 2 | 0 | Canadian Myeloma Research GroupOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT02597062 | High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma | completed | Phase 2 | 76 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 28, 2023 | clinicaltrials |
| NCT04309981 | Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody. | unknown | Phase 1 / Phase 2 | 73 | Sara V. LatorreOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT02906332 | Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM) | terminated | Phase 2 | 12 | Hackensack Meridian HealthOTHER | 1 | Aug 22, 2023 | clinicaltrials |
| NCT04445701 | Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 10 | Arch OncologyINDUSTRY | 1 | Aug 22, 2023 | clinicaltrials |
| NCT04119336 | Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma | terminated | Phase 2 | 2 | Andrew Yee, MDOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT01145989 | A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 8 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03215524 | A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide(DCDP) | completed | Phase 2 | 120 | Canadian Myeloma Research GroupOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03959358 | A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders | completed | Phase 2 | 10 | University Health Network, TorontoOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT03695744 | Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma | unknown | Phase 2 | 27 | Singapore General HospitalOTHER | 1 | Jul 10, 2023 | clinicaltrials |
| NCT02185820 | Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)(CPD) | completed | Phase 1 / Phase 2 | 57 | European Myeloma Network B.V.NETWORK | 1 | Jul 3, 2023 | clinicaltrials |
| NCT02204241 | Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients(CCD) | completed | Phase 1 / Phase 2 | 36 | European Myeloma Network B.V.NETWORK | 1 | Jul 3, 2023 | clinicaltrials |
| NCT01160107 | Revlimid And Prednisone Followed By Revlimid, Melphalan And Prednisone In Multiple Myeloma Patients(RP_MPR) | completed | Phase 2 | 46 | Fondazione EMN Italy OnlusOTHER | 0 | Jun 29, 2023 | clinicaltrials |
| NCT01166113 | Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma (MM) Relapsed and/or Refractory to Lenalidomide(PCP) | completed | Phase 1 / Phase 2 | 67 | Fondazione EMN Italy OnlusOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT01572662 | Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning | completed | Phase 2 | 201 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT01348919 | Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 11 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 2 | Jun 28, 2023 | clinicaltrials |
| NCT04814615 | A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma | unknown | Phase 2 | 60 | Hoag Memorial Hospital PresbyterianOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT02794246 | CART-19 Post-ASCT for Multiple Myeloma | terminated | Phase 2 | 6 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03782064 | Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma | terminated | Phase 2 | 5 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03809780 | Study to Demonstrate Clinical Benefit of Lenalidomide and Dexamethasone(LENDER) | unknown | Phase 2 | 70 | Kosin University Gospel HospitalOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03641456 | VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma | unknown | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05909826 | Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM(KMM-KCd) | not yet recruiting | Phase 2 | 49 | Dong-A University HospitalOTHER | 0 | Jun 18, 2023 | clinicaltrials |
| NCT03944057 | A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma(MARCH) | completed | Phase 2 | 82 | Antengene CorporationINDUSTRY | 1 | Jun 15, 2023 | clinicaltrials |
| NCT02903381 | A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma | completed | Phase 2 | 8 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 13, 2023 | clinicaltrials |
| NCT03090659 | LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma(LEGEND-2) | unknown | Phase 1 / Phase 2 | 100 | Nanjing Legend Biotech Co.INDUSTRY | 0 | Jun 12, 2023 | clinicaltrials |
| NCT02279394 | E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma | completed | Phase 2 | 51 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT01264315 | Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant | completed | Phase 2 | 53 | Fondazione EMN Italy OnlusOTHER | 1 | May 26, 2023 | clinicaltrials |
| NCT02416206 | High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma | completed | Phase 2 | 65 | Northside Hospital, Inc.OTHER | 1 | May 18, 2023 | clinicaltrials |
| NCT05857982 | Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 20 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT02751255 | Daratumumab in Combination With ATRA(DARA/ATRA) | completed | Phase 1 / Phase 2 | 60 | Amsterdam UMC, location VUmcOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT02581007 | Reduced Intensity Conditioning Transplant Using Haploidentical Donors | completed | Phase 2 | 25 | Northside Hospital, Inc.OTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT05393999 | SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations(SABRE) | withdrawn | Phase 2 | 0 | Imperial College Healthcare NHS TrustOTHER | 1 | Apr 24, 2023 | clinicaltrials |
| NCT05749133 | Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM | unknown | Phase 1 / Phase 2 | 18 | XuYanOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT04272151 | Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 40 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05308225 | Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 72 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Apr 12, 2023 | clinicaltrials |
| NCT01794520 | Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 117 | AbbVieINDUSTRY | 4 | Apr 10, 2023 | clinicaltrials |
| NCT01040026 | Expanded Natural Killer (NK) Cells for Multiple Myeloma Study | completed | Phase 1 / Phase 2 | 10 | University Hospital, Basel, SwitzerlandOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT03238599 | Pedometer Activity Monitoring After ASCT(PAMAL) | completed | Phase 2 | 62 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Apr 3, 2023 | clinicaltrials |
| NCT03411031 | Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide | terminated | Phase 2 | 18 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05521802 | A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 92 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Mar 24, 2023 | clinicaltrials |
| NCT04635735 | Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 3 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 23, 2023 | clinicaltrials |
| NCT03639610 | PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function(BRIDGE) | terminated | Phase 2 | 35 | Oncopeptides ABINDUSTRY | 3 | Mar 10, 2023 | clinicaltrials |
| NCT04674514 | APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 48 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Mar 7, 2023 | clinicaltrials |
| NCT03312530 | A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 49 | Hoffmann-La RocheINDUSTRY | 9 | Feb 28, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Sep 21, 2023source: clinicaltrials